Recursion Beats Q3 Revenue Estimates With $18.1M, Narrows Loss
RXRX sits 37% above its 52-week low of $2.77.
Summary
Recursion posted Q3 operating revenue of $18.055 million against an IBES estimate of $14.8 million, a clear beat. The net loss came in at $119.036 million versus the -$121.7 million consensus, so the loss was slightly smaller than expected. That follows Q2, when revenue of $7.3 million missed consensus by 39% on weaker Roche/Genentech collaboration revenue, so this quarter reverses that trend. The company is still burning heavily, with an operating loss of $123.176 million, and it raised $200 million in an October stock offering at $3.25 a share to fund that burn. The quarter also brought a $10 million Sanofi milestone, positive clinical data in REC-4881 and REC-1245, a Sanofi development candidate option, and the appointment of Fred Hassan as chair, and the company extended its cash runway. The revenue beat and narrower loss support the cost-cut story from Q2, when management lowered expense guidance and extended its cash runway.
At the time of this announcement, RXRX was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.77 to $5.76. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.